Genentech Presents Data for Hemlibra at the ISTH 2019 Congress

The following is an excerpt from a press release from Genentech. Read the press release in its entirety here.

Genentech, a member of the Roche Group, announced today new data for Hemlibra^® (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis 2019 Congress on July 6-10 in Melbourne, Australia.
In total, Genentech presented 21 abstracts from its hemophilia program, including five oral presentations. Further data from the four pivotal HAVEN clinical trials were presented, demonstrating the long-term safety, efficacy and quality of life benefit of Hemlibra in people with hemophilia A with and without factor VIII inhibitors. Genentech also presented the first interim analysis from the Phase IIIb STASEY study, reinforcing the safety profile of Hemlibra in adults and adolescents (aged 12 years or older) with hemophilia A with factor VIII inhibitors seen in the HAVEN 1 clinical trial.
“Data presented at ISTH continues to reinforce Hemlibra’s potential to redefine the standard of care for people living with hemophilia A,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are particularly excited to present the first interim analysis of safety data from the STASEY study, which adds to the growing body of evidence supporting Hemlibra as an important treatment option for people with hemophilia A.”
 
Read the press release in its entirety here.